Mantomed

Memantine hydrochloride, the active ingredient in Mantomed, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adults and works by reducing excitotoxic neuronal damage.

GNH USA supplies Mantomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mantomed belongs to the NMDA receptor antagonist class and is used in the management of neurodegenerative conditions. - Alzheimer’s disease: helps improve cognition and daily functioning in patients with moderate to severe disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: occasional disorientation. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm.

Before prescribing Mantomed, clinicians should consider several safety factors. - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - History of seizures: use with caution. - Concomitant NMDA antagonists: avoid combined use. - Pregnancy: safety not established; weigh risks and benefits. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Memantine may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Other NMDA antagonists (e.g., amantadine, dextromethorphan): additive neuro‑blocking effects. - High‑dose aspirin: may increase risk of gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil): monitor for enhanced cholinergic effects. - CNS depressants (e.g., benzodiazepines): observe for increased sedation. - Diuretics (e.g., furosemide): watch for electrolyte disturbances.